Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

WEB-2086

PAF receptor ligand
 
BML-L137-0001 1 mg 93.00 USD
 
BML-L137-0005 5 mg 373.00 USD
Do you need bulk/larger quantities?
 
PAF receptor antagonist. Inhibits PAF-induced human platelet and neutrophil aggregation in vitro (IC50=0.17 and 0.36µM respectively). In vivo it dose dependently blocks eosinophil activation and displays antiallergic and anti-inflammatory activity in various models. Induces differentiation and triggers apoptosis and in a variety of cell lines.

Product Specification

Formula:C22H22ClN5O2S
 
MW:456
 
CAS:105219-56-5
 
Purity:≥98% (HPLC)
 
Identity:Determined by 1H-NMR.
 
Appearance:Beige solid.
 
Solubility:Soluble in DMSO or ethanol.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Handling:Store dessicated.
 
Regulatory Status:RUO - Research Use Only
 
bml-l137
Please mouse over
bml-l137

Product Literature References

WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential: A. Laurenzana, et al.; Leukemia 19, 390 (2005), Abstract;
Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs: M. Kato, et al.; J. Pharmacol. Sci. 95, 435 (2004), Abstract;
Platelet-activating factor induces lung inflammation and leak in rats: hydrogen peroxide production along neutrophil-lung endothelial cell interfaces: Y.M. Lee, et al.; J. Lab. Clin. Med. 140, 312 (2002), Abstract;
Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells: C. Cellai, et al.; FASEB J. 16, 733 (2002), Abstract; Full Text
Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor: J. Casals-Stenzel, et al.; J. Pharmacol. Exp. Ther. 241, 974 (1987), Abstract;

Recommend this page

 
Keep in touch

©2020 Enzo Life Sciences, Inc.,